文献速递主动脉疾病

四分支即用型腔内移植物治疗肾旁及IV型胸腹主动脉瘤的关键试验1年结果

One-year outcomes from the pivotal trial of a four-branch off-the-shelf solution to treat pararenal and extent IV thoracoabdominal aortic aneurysms.
PubMed 文献 · J Vasc Surg · 2025-06-04

1年全因死亡率6例,无病变相关死亡,全因死亡免除率94.1%±2.3%;肾动脉闭塞是主要不良事件,与PRAA及肾动脉直径<5 mm相关。

要点

  • 1年全因死亡免除率94.1%±2.3%,无病变相关死亡。
  • 至少一支靶血管分支闭塞发生率为14.7%。
  • 肾动脉直径<5 mm者肾动脉闭塞风险更高(OR 3.04)。

核心结论

  • 治疗后1年死亡率低,但肾动脉闭塞是主要不良事件,主要与PRAA和较小肾血管直径相关。

主要发现

  • 1年时8例失访,6例死亡(1例器械相关、1例操作相关、4例无关原因),无病变相关死亡,全因死亡免除率94.1%±2.3%。
  • IV型TAAA患者1年无「临床显著再干预」且无病变相关死亡的复合终点达成率为78.7%,PRAA患者为60.5%(P = .09)。
  • 至少一支靶血管分支闭塞发生率为14.7%;血管水平1年无靶血管不稳定的比例为94.2%±1.2%(腹腔干99.0%±1.0%,肠系膜上动脉97.1%±1.7%,右肾动脉90.8%±2.9%,左肾动脉89.8%±3.1%)。
  • 肾动脉闭塞在直径<5 mm的动脉中更常见(OR = 3.04;95%CI:1.08,8.54),在PRAA患者中更常见(OR = 2.85;95%CI:0.88,9.25,无统计学意义)。
  • 15例患者共22次再干预,其中16次(73%)为轻微再干预:13次(81%)针对靶血管并发症,3次(19%)针对II型内漏;6例患者发生器械或操作相关重大再干预,包括靶血管闭塞的血栓切除或溶栓(5例)和操作中主动脉破裂后的剖腹探查(1例)。

临床怎么用

  • 随访中应关注肾分支评估,以识别有闭塞风险的患者。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report 1-year primary-arm outcomes of the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis pivotal trial. METHODS: The multicenter, nonrandomized, prospective study included patients with extent IV thoracoabdominal aortic aneurysms (TAAAs) and pararenal aortic aneurysms (PRAAs). All-cause and adjudicated lesion-related mortality were assessed at 12 months. Core-lab-reported, imaging-dependent outcomes included aneurysm size, endoleaks assessed through 1-year follow-up window, and target vessel instability (defined as occlusion, stenosis, type Ic/IIIc endoleak, or reintervention) at 1 year. RESULTS: One hundred two patients were treated; 59 patients had an extent IV TAAA and 43 had a PRAA. The mean maximum aneurysm diameter was 59.4 ± 7.8 mm. At 1 year, eight patients were lost to follow-up and six patients died (1 device-related, 1 procedure-related, and 4 unrelated causes). No lesion-related mortality occurred. Freedom from all-cause mortality was 94.1% ± 2.3%. The 1-year combined freedom from "clinically significant reintervention" and lesion-related mortality was achieved in 78.7% and 60.5% of patients with extent IV TAAAs and PRAAs, respectively (P = .09). At least one target vessel branch occlusion occurred in 14.7% of patients through 1 year of follow-up. At the vessel level, freedom from target vessel instability at 1 year was 94.2% ± 1.2% (celiac 99.0% ± 1.0%, superior mesenteric 97.1% ± 1.7%, right renal 90.8% ± 2.9%, and left renal 89.8% ± 3.1%). Acute kidney injury requiring dialysis occurred in three patients (n = 2 permanent, n = 1 temporary) through 1 year. Renal artery occlusion occurred more often in arteries with diameters <5 mm (odds ratio = 3.04; 95% confidence interval: 1.08, 8.54) and in patients with pararenal aneurysms (odds ratio = 2.85; 95% confidence interval: 0.88, 9.25, statistically insignificant). Of the 22 reinterventions in 15 patients, 16 (73%) reinterventions were classified as minor: 13 (81%) for target vessel complications and 3 (19%) for type II endoleaks. Device- or procedure-related major reinterventions in six patients included thrombectomy or thrombolysis for target vessel occlusion (n = 5) and one exploratory laparotomy after procedural aortic rupture. No type I/III endoleaks were identified (Core Lab) through 1 year. Aortic enlargement (>5 mm) occurred in 5 patients (6.0%). Aneurysm shrinkage (>5 mm) occurred in 20 patients (23.8%). Aortic component fractures identified in 3 patients (3.6%) were clinically insignificant. CONCLUSIONS: Although mortality remains low 1 year after treatment with the GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis device for extent IV and pararenal aneurysms, renal artery occlusion was the predominant adverse event and was primarily associated with PRAAs and smaller renal vessel diameters. During extended follow-up, attention should be focused on renal branch assessment to identify patients at risk for occlusion.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Farber MA, Han S, Makaroun MS, et al. One-year outcomes from the pivotal trial of a four-branch off-the-shelf solution to treat pararenal and extent IV thoracoabdominal aortic aneurysms. J Vasc Surg. 2025. PMID: 40480617. doi:10.1016/j.jvs.2025.05.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。